Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced that RBD7022 Injection, its independently developed siRNA...
HKG: 6938
Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) has entered a landmark licensing agreement with Madrigal...
Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock...